STOCK TITAN

Gilead (NASDAQ: GILD) grants RSUs and stock options to director Rodriguez

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gilead Sciences director Javier Rodriguez received new equity awards as part of his compensation. He was granted 1,146 restricted stock units, each representing one share of common stock, which vested immediately on April 30, 2026, raising his direct common stock holdings to 13,364 shares.

Rodriguez was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share. All of these option shares vested immediately on April 30, 2026 and are scheduled to remain exercisable until April 30, 2036.

Positive

  • None.

Negative

  • None.
Insider Rodriguez Javier
Role null
Type Security Shares Price Value
Grant/Award Non-qualified Stock Option (Right to Buy) 4,884 $0.00 --
Grant/Award Common Stock 1,146 $0.00 --
Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 4,884 shares (Direct, null); Common Stock — 13,364 shares (Direct, null)
Footnotes (1)
  1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.
Restricted stock units granted 1,146 RSUs Granted and vested immediately on April 30, 2026
Common shares after grant 13,364 shares Direct common stock holdings following RSU grant
Stock options granted 4,884 options Non-qualified stock option, fully vested on April 30, 2026
Option exercise price $130.84 per share Conversion or exercise price for 4,884-option grant
Option expiration date April 30, 2036 Expiration for non-qualified stock option grant
restricted stock units financial
"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Equity Incentive Plan financial
"granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Non-qualified Stock Option financial
"Non-qualified Stock Option (Right to Buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
vested immediately financial
"The RSUs vested immediately upon the grant date of April 30, 2026."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rodriguez Javier

(Last)(First)(Middle)
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CALIFORNIA 94404

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)04/30/2026A1,146A$013,364D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified Stock Option (Right to Buy)$130.8404/30/2026A4,884 (2)04/30/2036Common Stock4,884$04,884D
Explanation of Responses:
1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.
Remarks:
/s/ Amy Kim by Power of Attorney for Javier J. Rodriguez05/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Gilead Sciences (GILD) director Javier Rodriguez receive?

Javier Rodriguez received 1,146 restricted stock units and a non-qualified stock option for 4,884 shares. Each RSU equals one Gilead common share, and the option allows him to buy additional shares at a fixed $130.84 exercise price.

When did Javier Rodriguez’s new Gilead (GILD) RSUs and options vest?

Both the 1,146 restricted stock units and all 4,884 stock option shares vested immediately on April 30, 2026. Immediate vesting means Rodriguez gained the full rights under these awards as of that grant date, subject to plan and agreement terms.

How many Gilead (GILD) shares does Javier Rodriguez hold after this Form 4?

After the RSU grant, Javier Rodriguez directly holds 13,364 Gilead common shares. This figure reflects his position following the acquisition of 1,146 restricted stock units that each represent one share of Gilead’s common stock under the equity plan.

What is the exercise price and term of Javier Rodriguez’s Gilead stock options?

The non-qualified stock option covers 4,884 Gilead shares at a $130.84 exercise price. All shares vested immediately and the option is scheduled to remain exercisable until April 30, 2036, providing a long-dated right to purchase stock at that price.

Are Javier Rodriguez’s Gilead (GILD) Form 4 transactions open-market buys or sales?

The filing shows compensation-related acquisitions, not open-market trades. Rodriguez received restricted stock units and a stock option grant from Gilead, both at a grant price of $0.00 per share, rather than purchasing or selling shares in the open market.